section name header
Index
Air Travel and Prevention of Venous Thromboembolism by Medication
Anticoagulants for Acute Ischaemic Stroke
Anticoagulation for the Intial Treatment of Venous Thromboembolism in Patients with Cancer
Anticoagulation for the Long Term Treatment of Venous Thromboembolism in Patients with Cancer
Fondaparinux in the Prevention of Venous Thromboembolism after Surgery
Heparin for the Prevention of Venous Thromboembolism in General Medical Patients (Excluding Stroke and Myocardial Infarction)
Interventions for Preventing Venous Thromboembolism in Adults Undergoing Knee Arthroscopy
Low Molecular Weight Heparin in Patients with Lower-Leg Immobilization
Low-Molecular-Weight-Heparins Compared to Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction Treated with Thrombolysis
Low Molecular Weight Heparins for Acute Coronary Syndromes
Low-Molecular-Weight Heparins Vs. Standard Heparin for Acute Ischaemic Stroke
Prolonged Thromboprophylaxis with Low Molecular Weight Heparin for Abdominal or Pelvic Surgery
Risk for Heparin-Induced Thrombocytopenia (HIT) with Either Low-Molecular-Weight Heparin (Lmwh) or Unfractionated Heparin (Ufh)
Vitamin K Antagonists or Low-Molecular Weight Heparin for Venous Thromboembolism